KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Prepaid Assets (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Prepaid Assets data on record, last reported at $32.6 million in Q4 2025.

  • For Q4 2025, Prepaid Assets rose 48.74% year-over-year to $32.6 million; the TTM value through Dec 2025 reached $32.6 million, up 48.74%, while the annual FY2025 figure was $32.6 million, 48.74% up from the prior year.
  • Prepaid Assets reached $32.6 million in Q4 2025 per PCRX's latest filing, down from $43.5 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $43.5 million in Q3 2025 and bottomed at $11.3 million in Q3 2021.
  • Average Prepaid Assets over 5 years is $20.8 million, with a median of $18.7 million recorded in 2023.
  • Peak YoY movement for Prepaid Assets: tumbled 32.55% in 2021, then skyrocketed 88.25% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $14.8 million in 2021, then grew by 3.06% to $15.2 million in 2022, then skyrocketed by 41.26% to $21.5 million in 2023, then grew by 1.98% to $21.9 million in 2024, then soared by 48.74% to $32.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Prepaid Assets were $32.6 million in Q4 2025, $43.5 million in Q3 2025, and $37.2 million in Q2 2025.